Nasal Vaccines Market, By Vaccine Type (Live attenuated vaccines, Inactivated vaccines, Subunit, recombinant, and conjugate vaccines, and Others (such as DNA vaccines, viral vector vaccines, etc.)), By Application (Influenza, COVID-19, Other respiratory infections (such as RSV, pneumococcal, etc.) and Others (such as cholera, etc.)), By Distribution Channel (Public and Private ), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Published In : Nov 2023

Code : CMI5818

Pages :160

Formats :

Excel and PDF

Industry : Pharmaceutical

Nasal Vaccines MarketSize and Trends

The global nasal vaccines market size was valued at US$ 416.8 million in 2023 and is expected to reach US$ 742.6 million by 2030, grow at a Compound Annual Growth Rate (CAGR) of 8.6% from 2023 to 2030.

The nasal vaccines market refers to the segment of the pharmaceutical industry that focuses on the development, production, and distribution of vaccines administered through the nasal route. Nasal vaccines are a type of immunization that is delivered via intranasal administration, typically in the form of a nasal spray. These vaccines are designed to stimulate an immune response in the mucosal surfaces of the respiratory tract, providing protection against respiratory infections caused by specific pathogens such as influenza, COVID-19, and others.

The nasal vaccines market has witnessed significant growth in recent years, driven by factors such as the increasing demand for needle-free vaccine delivery methods, the potential for enhanced mucosal immunity, ease of administration, and potential for improved patient compliance, particularly in the pediatric population. Nasal vaccines are being developed for a range of infectious diseases, and ongoing research aims to expand their applications.

Nasal Vaccines Market Trends:

Advancements in vaccine delivery technologies: The nasal vaccines market has witnessed advancements in vaccine delivery technologies. This includes the development of improved nasal spray devices, innovative formulations, and delivery systems that enhance vaccine stability, mucosal targeting, and immune response. Market players are focused on the partnerships for the development of nasal spray vaccines. For instance, In March 2021, Altimmune, a clinical-stage biopharmaceutical company, and Summit Biosciences, a global player in nasal spray pharmaceuticals, announced a partnership to manufacture a metered nasal spray presentation of AdCOVID, its intranasal COVID-19 vaccine candidate.
Increased focus on respiratory pathogens: There is a heightened focus on developing nasal vaccines for respiratory pathogens, especially in light of the COVID-19 pandemic. The need for effective prevention and control of respiratory infections has accelerated research and development efforts in this area.
Development of needle-free pediatric vaccines: Nasal vaccines are gaining traction as a needle-free alternative for pediatric vaccinations. The ease of administration, reduced pain, and potential for improved compliance make them attractive for immunizing children against respiratory diseases
Expansion of immunization programs: Nasal vaccines are being included in national immunization programs in various countries. Governments and public health agencies are recognizing the benefits of nasal vaccines, leading to their inclusion for the prevention of respiratory infections such as influenza.